DO-BO

New book: Digital Healthcare in Germany

We are happy to introduce the new book by Dr. Stefan Walzer on Digital Healthcare in Germany:

Digital Healthcare in Germany

Digital healthcare is heterogeneous along the entire treatment pathway, ranging from monitoring applications and artificial-intelligence-based diagnostics, to support for virtual reality surgery. Since the introduction of the Digital Health Act in Germany in early 2020, there has been a push toward digital innovative solutions, especially in the outpatient sector.

This book analyzes current digital health law from an economic perspective, combining theory with real-world applications. It examines both the incentives and market access pathways for digital solutions and the price effects brought about by the new regulatory framework in Germany. Further, it discusses the difficulties in pricing due to the monopolistic BfArM register and negotiations with the association of all German health insurance companies.

The book addresses a wide range of topics, including incentives for innovation, specifics of digital health applications, reimbursement and financing options for digital health solutions. Lastly, it presents an outlook for the future and a comparison between Germany and other countries, namely the USA and Japan. Given its scope, this book will appeal to scholars of health economics, healthcare management and public health, as well as practitioners and professionals in the public health sector.

Please find the book “Digital Healthcare in Germany” at Springer LinkAmazon, or wherever books are sold.

Related

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]